Premium
P4‐380: BACE Inhibitor Verubecestat (MK‐8931): Baseline Characteristics for Participants Enrolled in the Phase II/III Epoch Alzheimer’S Disease Trial
Author(s) -
Egan Michael,
Voss Tiffini,
Mo Yi,
Mukai Yuki,
Furtek Christine,
Kost James,
Aisen Paul S.,
Cummings Jeffrey L.,
Tariot Pierre N.,
Vellas Bruno,
Michelson David
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.07.126
Subject(s) - medicine , memantine , placebo , randomized controlled trial , clinical trial , donepezil , disease , dementia , pathology , alternative medicine
is known about whether disclosing amyloid PET results of preclinical AD has any adverse psychological effects on older adults in Japan who are cognitively normal. The aim of the present research is to investigate psychological impact of diagnostic disclosure of AD in cognitively normal Japanese elderly. Methods:We recruited 25 cognitively normal outpatients of the memory clinic at Keio University Hospital, complaining about cognitive declines. All participants completed the amyloid PET, and 18 entered a 6-week follow-up phase (8 females, mean age6S.D.1⁄4 75.865.3 years). They were divided into amyloid-positive (n1⁄4 4) and negative (n1⁄414) groups. First, we conducted a paired t-test to compare scores of the state anxiety and trait anxiety as measured by the State-Trait Anxiety Inventory (STAI), and depression as measured by the Beck Depression Inventory-II (BDI-II) in each group at baseline and 6 weeks after disclosure. Also, the Impact of Event ScaleRevised (IES-R) was measured at 6 weeks in each group. Second, we compared two groups in changes to the scores of all the measures by using an independent t-test. All statistical tests were 2tailed and P<0.05 was considered to indicate statistical significance. Results:There were no significant differences between baseline and post-disclosure scores of state anxiety, trait anxiety, and depression in the amyloid-positive group (D1⁄4-5.75, -3.25, 1.50, respectively) and the amyloid-negative group (D1⁄41.43, 2.29, 2.86, respectively). Compared with the amyloid-negative group, the amyloid-positive group showed no significant changes from baseline in the three measures. The IES-R mean scores at 6 weeks in each group were well below the cutoff score (6.00 and 10.5, respectively). We observed no significant difference between groups in test-related distress. Conclusions:The disclosure of amyloid PET results to elderly Japanese people did not cause any significant adverse psychological impacts in a short period of time. Japanese individuals who received a positive amyloid scan result showed no greater mood disturbance than those who received a negative result.